Evgen Pharma (GB:TCF) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
James Robert Kight has increased his stake in Theracryf PLC, with the acquisition of additional voting rights, now holding a total of 8.09647% or 34,600,000 voting rights. The notification was filed on July 17, 2024, after the threshold was crossed on the previous day. This move might suggest a growing confidence in the company’s prospects, which could interest investors tracking shareholder activity for investment insights.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.